Dr. Diwakar Davar, MD
Claim this profileUPMC Hillman Cancer Center
About Diwakar Davar, MD
Education:
- Earned an MD (M.B.B.S.) from the National University of Singapore in 2005.
- Completed an MSc at the University of Pittsburgh in 2016.
Experience:
- Serves as an Associate Professor of Medicine at the University of Pittsburgh Cancer Institute and UPMC Hillman Cancer Center.
- Focuses on translational cancer immunotherapy and early-phase clinical trials.
- Engaged in collaborative clinical trials on PD-1 inhibitors and other immunotherapies.
- Presented preliminary results at ASCO 2015 and led first-in-human studies in immunotherapy.
Area of expertise
Melanoma
Diwakar Davar, MD has run 19 trials for Melanoma. Some of their research focus areas include:
Cancer
Diwakar Davar, MD has run 9 trials for Cancer. Some of their research focus areas include:
Affiliated Hospitals
UPMC Hillman Cancer Center
University Of Pittsburgh Cancer Institute (UPCI)
Clinical Trials Diwakar Davar, MD is currently running
Immunotherapy + Prednisone + Sirolimus
for Skin Cancer
This phase II trial tests the combination of nivolumab and ipilimumab with sirolimus and prednisone for the treatment of skin (cutaneous) cancer that cannot be removed by surgery (unresectable) or that has spread from where it first started to other places in the body (metastatic) in kidney transplant recipients. Immunotherapy with nivolumab and ipilimumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Sirolimus and prednisone are immunosuppressants that are given to keep the body from rejecting the transplanted kidney. Giving nivolumab and ipilimumab in combination with sirolimus and prednisone may kill more cancer cells, while also keeping the transplanted kidney healthy, in patients with unresectable or metastatic cutaneous cancer who have received a kidney transplant.
Recruiting
1 award
Phase 1 & 2
10 criteria
Microbiome Treatment
for Colitis
Multiple retrospective studies suggest that the administration of corticosteroids to treat irAEs is safe, and does not compromise efficacy of ICI therapy in cancer patients. While \~67% of patients respond to corticosteroids, 33% of patients require biologic therapy such as TNFα inhibitors (e.g. infliximab), integrin α4β7 inhibitors (e.g. vedolizumab), or JAK/STAT inhibitors (e.g. tofactinib). This study aims to determine that distinct pathobionts govern the development of irCAE and IMC; and that the administration of hdFMT may reverse steroid-refractory irCAEs or IMC. The use of hdFMT has been shown to be effective in steroid and biologic (TNFα and/or integrin α₄β₇ inhibitor) refractory colitis in PD-1 and/or CTLA-4 ICI treated cancer patients in single-institution case series.
Recruiting
1 award
Phase 2
5 criteria
More about Diwakar Davar, MD
Clinical Trial Related
7 years of experience running clinical trials · Led 34 trials as a Principal Investigator · 7 Active Clinical Trials
Treatments Diwakar Davar, MD has experience with
- Nivolumab
- Pembrolizumab
- Ipilimumab
- Dabrafenib Mesylate
- Trametinib Dimethyl Sulfoxide
- TSR-022
Breakdown of trials Diwakar Davar, MD has run
Melanoma
Cancer
Solid Tumors
Skin Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Diwakar Davar, MD specialize in?
Diwakar Davar, MD focuses on Melanoma and Cancer. In particular, much of their work with Melanoma has involved Stage IV patients, or patients who are BRAF positive.
Is Diwakar Davar, MD currently recruiting for clinical trials?
Yes, Diwakar Davar, MD is currently recruiting for 7 clinical trials in Pittsburgh Pennsylvania. If you're interested in participating, you should apply.
Are there any treatments that Diwakar Davar, MD has studied deeply?
Yes, Diwakar Davar, MD has studied treatments such as Nivolumab, Pembrolizumab, Ipilimumab.
What is the best way to schedule an appointment with Diwakar Davar, MD?
Apply for one of the trials that Diwakar Davar, MD is conducting.
What is the office address of Diwakar Davar, MD?
The office of Diwakar Davar, MD is located at: UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania 15232 United States. This is the address for their practice at the UPMC Hillman Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.